We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
+0.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$414M
AUM Growth
-$36.3M
(-8.1%)
Cap. Flow
-$29.4M
Cap. Flow
% of AUM
-7.11%
Top 10 Holdings %
Top 10 Hldgs %
59.21%
Holding
41
New
5
Increased
13
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$22.5M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
+$16.4M |
| 3 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$14.1M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$11.9M |
| 5 |
Cytokinetics
CYTK
|
+$10.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$49.3M |
| 2 |
BioAtla
BCAB
|
+$17M |
| 3 |
MacroGenics
MGNX
|
+$16.1M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$13.1M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$10.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.8% |
| 2 | Real Estate | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dianthus Therapeutics
DNTH
$5.84B
| $3.39M | 0.82% |
73,125
| – | – |
|
|
CINC
27
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $1.4M | 0.34% |
+79,670
| New | +$1.63M |
|
28
CALL
Nektar Therapeutics
NKTR
$2.39B
| $539K | 0.13% |
6,667
-6,926
| -51% | -$1.03M |
|
29
Passage Bio
PASG
$14.4M
| $353K | 0.09% |
5,695
-70,210
| -92% | -$5.79M |
|
30
Rafael Holdings
RFL
$101M
| $304K | 0.07% |
122,694
-167,020
| -58% | -$573K |
|
31
Arbutus Biopharma
ABUS
$857M
| – | – |
-668,907
| Closed | -$2.6M |
|
|
32
BioAtla
BCAB
$5.46M
| – | – |
-17,286
| Closed | -$17M |
|
33
Cabaletta Bio
CABA
$437M
| – | – |
-472,433
| Closed | -$1.79M |
|
34
Dyne Therapeutics
DYN
$4.7B
| – | – |
-845,000
| Closed | -$10M |
|
|
35
MacroGenics
MGNX
$235M
| – | – |
-1,000,000
| Closed | -$16.1M |
|
36
ProQR Therapeutics
PRQR
$243M
| – | – |
-1,121,122
| Closed | -$8.98M |
|
37
Pyxis Oncology
PYXS
$168M
| – | – |
-400,000
| Closed | -$4.39M |
|
|
38
Rocket Pharmaceuticals
RCKT
$340M
| – | – |
-500,526
| Closed | -$10.9M |
|
|
39
Sarepta Therapeutics
SRPT
$1.57B
| – | – |
-145,405
| Closed | -$13.1M |
|
40
Spyre Therapeutics
SYRE
$8.54B
| – | – |
-36,410
| Closed | -$4.32M |
|
|
ARNA
41
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-530,670
| Closed | -$49.3M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q1 2022 Portfolio in Review
As of Q1 2022, Great Point Partners held 41 positions worth $414M, down 8.1% from $450M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Great Point Partners withdrew a net $29.4M in Q1 2022, closing 11 positions and reducing 7 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $49.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Real Estate.
Against the trend, Great Point Partners opened a new position in Jazz Pharmaceuticals worth $24.1M.
- Great Point Partners's largest Q1 2022 buy was Jazz Pharmaceuticals: 155,000 shares worth $24.1M.
- Great Point Partners added most to Bicycle Therapeutics in Q1 2022, an estimated $16.4M increase.
- Great Point Partners's biggest Q1 2022 reduction was Exelixis, cutting an estimated $8.79M.
- Great Point Partners fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $49.3M.
- Great Point Partners's ten largest holdings make up 59% of its $414M portfolio in Q1 2022.
- Great Point Partners opened 5 new positions and closed 11 in Q1 2022.
- Great Point Partners's portfolio value fell 8.1% quarter-over-quarter to $414M.
Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.